Drugs / KSHN001034
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06995482 | Aug 2025 → May 2026 overdue | — | Kashiv BioSciences, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSHN001034 | “Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant.” NCT06995482 ↗ |
| Route | Intramuscular | “6 subjects will receive low dose of KSHN001034 IM on Days 1, 8, 15, and 22.” NCT06995482 ↗ |